. 2006 Oct;50(10):3289–3296. doi: 10.1128/AAC.00699-06

TABLE 2.

CI values for inhibition of HIV-1 reporter viruses pseudotyped with envelopes from HIV-1_JR-FL and HIV-1_SF162^a

First inhibitor	Target	HIV-1 envelope	IC₅₀ (nM)	IC₉₀ (nM)	Second inhibitor	CI₅₀	P value	CI₉₀	P value
PRO 140	CCR5	JR-FL	2.2	28	PRO 140	1.2 ± 0.32	0.16	0.90 ± 0.15	0.047
		SF162	1.3	20	PRO 140	1.0 ± 0.27	1.0	0.86 ± 0.33	0.21
Vicriviroc	CCR5	JR-FL	2.4	44	PRO 140	*0.47 ± 0.15*	<*0.001*	*0.18 ± 0.04*	<*0.001*
		SF162	0.34	14	PRO 140	*0.60 ± 0.17*	<*0.001*	*0.28 ± 0.11*	<*0.001*
Maraviroc	CCR5	JR-FL	7.4	46	PRO 140	*0.44 ± 0.06*	<*0.001*	*0.24 ± 0.11*	<*0.001*
		SF162	0.87	13	PRO 140	*0.64 ± 0.07*	<*0.001*	*0.31 ± 0.11*	<*0.001*
Maraviroc	CCR5	JR-FL	7.4	46	Vicriviroc	0.71 ± 0.11	0.16	1.2 ± 0.15	0.32
		SF162	0.87	13	Vicriviroc	0.87 ± 0.06	0.19	0.86 ± 0.28	0.61
2D7	CCR5	JR-FL	8.8	>200	PRO 140	1.5 ± 0.25	0.024	NA	NA
		SF162	2.2	74	PRO 140	1.1 ± 0.47	0.61	1.0 ± 0.16	0.65
PRO 542	gp120	JR-FL	0.19	2.9	PRO 140	1.2 ± 0.32	0.22	1.0 ± 0.18	0.92
		SF162	0.36	7.1	PRO 140	0.98 ± 0.28	0.84	0.64 ± 0.26	0.010
BMS-378806	gp120	JR-FL	1.2	11	PRO 140	1.2 ± 0.38	0.43	0.74 ± 0.23	0.059
		SF162	0.03	0.42	PRO 140	1.1 ± 0.28	0.36	0.82 ± 0.21	0.068
Nevirapine	RT	JR-FL	30	310	PRO 140	1.2 ± 0.38	0.36	0.73 ± 0.28	0.068
		SF162	42	280	PRO 140	1.2 ± 0.34	0.30	0.63 ± 0.19	0.033
Zidovudine	RT	JR-FL	140	1900	PRO 140	1.1 ± 0.38	0.37	0.85 ± 0.26	0.21
		SF162	86	2100	PRO 140	0.99 ± 0.27	0.91	1.0 ± 0.38	1.0

Statistically significant results (P < 0.0016 after application of the Bonferroni correction for multiple comparisons) are indicated in italicized bold text. IC₅₀ and IC₉₀ refer to values for the first inhibitor. RT, reverse transcriptase; NA, not applicable. 2D7 did not consistently achieve 90% inhibition in the assay. CI values represent the means and standard deviations of four or more independent assays.